Nasdaq

Sionna Therapeutics Completes Phase 1 Dosing for NBD1 Stabilizers SION-719 and SION-451, Reports Strong Financial Position and Upcoming Milestones

Sionna Therapeutics completes Phase 1 dosing for NBD1 stabilizers SION-719 and SION-451, with Phase 2a trials set for 2025. Sionna Therapeutics announced the completion of Phase 1 dosing for its NBD1 ...
Nasdaq

Sionna Therapeutics Completes Phase 1 MAD Dosing for SION-451, Plans Final Cohort for SION-719, and Reports Positive Interim Data with Upcoming IPO Proceeds Strengthening ...

Sionna Therapeutics, Inc. has successfully completed the Phase 1 multiple ascending dose (MAD) trial for SION-451 and plans to finalize the MAD cohort for SION-719, with interim results in healthy ...